-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GmWgB8KokAeC/xumV+e+xakMNYcHAwP7oONT3GCC4aGdLDwxlTT3M6ahI+5SrzRe
 EXN7di55pgcdk4NRaRdP8A==

<SEC-DOCUMENT>0001119774-04-000016.txt : 20040719
<SEC-HEADER>0001119774-04-000016.hdr.sgml : 20040719
<ACCEPTANCE-DATETIME>20040719074811
ACCESSION NUMBER:		0001119774-04-000016
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040701
FILED AS OF DATE:		20040719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		04919109

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		STREET 2:		TEL AVIV
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sixkjuly42004.htm
<DESCRIPTION>JULY 1ST, 2004 6K
<TEXT>
<html>
<head>
<meta name=Generator content="Microsoft Word 10 (filtered)">
<title>6-kjuly42004</title>

<!--
 /* Font Definitions */
 @font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
h1
	{margin:0in;
	margin-bottom:.0001pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h2
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:black;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;}
div.Section1
	{page:Section1;}
- -->

</head>
<body lang=EN-US>
<div class=Section1>
<p  Style="margin-left:.75in;margin:0in;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman""><b>&nbsp;</b></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>FORM 6-K</b></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>SECURITIES AND
EXCHANGE COMMISSION</b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><i
style='font-size:11.0pt'>&nbsp;</i></b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>Washington, D.C. 20549</b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><i
style='font-size:11.0pt'>&nbsp;</i></b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>Report of Foreign Private Issuer</b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><i
style='font-size:11.0pt'>&nbsp;</i></b></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to rule 13a-16 or 15d-16 of the Securities
Exchange Act of 1934</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">for the month of February 2004</p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>Compugen Ltd.</u></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Translation of registrant's name in English)</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>72 Pinchas Rosen Street, Tel-Aviv 69512, Israel</u></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Address of principal executive offices)</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="text-align:justify;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F.</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Form 20-F&nbsp;&nbsp;<u> X&nbsp;&nbsp;</u>             Form
40-F&nbsp;___</p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="text-align:justify;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">On July 1st, 2004 Compugen Ltd. (the
&quot;Registrant&quot;) issued a Press Release, filed as Exhibit 1 to this
Report on Form 6-K, which is hereby incorporated by reference herein.</p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>&nbsp;</b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><u style='font-size:11.0pt'>SIGNATURE</u></b></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="text-align:justify;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</p>
<p  Style="margin-left:28.35pt;margin-right:28.35pt;margin-top:0in;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-left:4.0in; margin-bottom:.0001pt;margin-right:28.35pt;margin-top:0in;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">                                    </p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen Ltd.</p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Registrant)</p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">By:    <u>/s/ Mor Amitai</u></p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Title:  President &amp; CEO</p>
<p  Style="text-indent:225.0pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Date: July
1st, 2004</p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>Exhibit 1</b></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><img width=257
height=136 src="image001.jpg"></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>&nbsp;<!-- Created Using Viltech Software --></b></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>&nbsp;<!-- Created Using Viltech Software --></b></p>
<h2 Style="margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:black"> Compugen Establishes Small Molecule Drug Discovery Subsidiary</h2>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">Tel Aviv, Israel - July 1,
2004 - Compugen Ltd. <!-- Created Using Viltech Software -->(Nasdaq: CGEN) announced
today the establishment of a new subsidiary, Keddem Bioscience Ltd., focused on
small molecule drug discovery. The program now being transferred to the new
company was initiated in 2000 as the chemistry division of Compugen.&nbsp;&nbsp;The
subsidiary`s offices and laboratories are located in Ashkelon, Israel. <!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">Keddem`s objective is to
dramatically improve the success rate for the development of new drug products
by developing and applying a technology platform that consistently enables the
design of small molecule modulators for potentially any given protein target.
Relevant targets may include difficult or intractable targets, such as protein-protein
interactions, many of which are considered well validated but have so far been
beyond the reach of conventional practices.<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">Identifying a lead chemical for a
potential target is a long and arduous undertaking, considered by many to be
the limiting factor in drug development. Common methods for finding such
molecules, typically variants of high-throughput screening of drug-like
compounds or protein structure-based drug design, suffer from low success rates
and often fail to find any candidate compound for a given target. <!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><br>
<!-- Created Using Viltech Software --></b>The Keddem approach is based on the
proposed creation of a comprehensive, yet relatively small set of carefully
designed molecules and a suite of algorithms. The set will consist of less than
100,000 molecules, mostly novel compounds that differ in several ways from
molecules in existing screening libraries. Although 100,000 compounds is a
small number compared to the millions typically used in screening libraries of
drug-like compounds, the Keddem screening set is designed to be truly
exhaustive, covering the relevant chemical space, and so should be equally
applicable to all targets.<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">When synthesized, the Keddem set
of molecules will be used in a screening process, with a functional assay for
the target of interest. Utilizing a suite of algorithms to analyze the
screening results, the platform is designed to provide comprehensive
three-dimensional information about the active site of the target. This
information then enables the design of a variety of potent inhibitors
satisfying desired drug-like properties.<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">"This initiative is another
example of the power in bringing the capabilities of physics, mathematics, and
computer science to the disciplines underlying pharmaceutical research," stated
Mor Amitai, Ph.D., President and Chief Executive Office of Compugen Ltd. "We
are very pleased that this activity has now matured to the point where
establishing it as a separate company provides the best opportunity to fulfill
its significant potential. At the same time," Dr. Amitai continued, "similar to
our decision to establish Evogene as our agbio subsidiary, this enables
Compugen to maintain its focus on predictive biology and on the creation and
use of discovery engines for new therapeutic proteins and diagnostic markers."<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">Keddem`s current research team
consists of professionals from the fields of physics, mathematics, chemistry,
and biochemistry.&nbsp;&nbsp;The Company is managed by Dr. Dror Ofer and Dr.
Arnon Levy. <!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">"Our technology aims at finding
small molecule drug candidates for any target protein, including the many
so-called `undruggables.` In our opinion, the discovery of effective new
molecular entities is the primary bottleneck of the pharmaceutical industry and
is unlikely to be alleviated by scale up or variation of current approaches, but
will require advanced scientific methodology such as ours," said Dror Ofer,
Ph.D., Co-Chief Executive Officer of Keddem Bioscience. "`Going back to the
basics` in this field is, in spite of the inherent uncertainties, no longer a
luxury but rather an imperative. We are enthusiastic about further developing
this radically new scientific approach as a separate company," Dr. Ofer
continued. <!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>About Compugen <!-- Created Using Viltech Software --></b></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">Compugen, a genomics-based drug
and diagnostic discovery company, increases the probability of successful
development of novel drug and diagnostic products by incorporating ideas and
methods from mathematics, computer science, and physics into the disciplines of
biology, organic chemistry, and medicine. This unique capability results in
powerful predictive models and discovery engines, which are both advancing the
understanding of important biological phenomena and enabling the discovery of
numerous potential therapeutic products and diagnostic markers. The Company has
an early stage in-house pipeline consisting of selected therapeutic protein
candidates discovered by the Company; additional discoveries have been
out-licensed for development. Among Compugen`s customers and partners are
leading pharmaceutical and diagnostic companies, such as Abbott Laboratories,
Diagnostic Products Corporation, Novartis, and Pfizer. For additional
information, please visit Compugen's corporate Website at <!-- Created Using Viltech Software --><u>www.cgen.com &lt;http://www.cgen.com&gt;<!-- Created Using Viltech Software --> &lt;<!-- Created Using Viltech Software -->&lt;http://www.cgen.com/?Z3PR&gt;<!-- Created Using Viltech Software -->&gt;<!-- Created Using Viltech Software --></u>. <!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p  Style="text-align:justify;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="color:black;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">This press
release contains &quot;forward-looking statements&quot; within the meaning of
the Private Securities Litigation Reform Act of 1995.<i
style='font-size:11.0pt;font-family:Verdana;color:black'>&nbsp;&nbsp;</i>These statements include words like
&quot;may,&quot; &quot;expects,&quot; &quot;believes,&quot; and
&quot;intends,&quot; and describe opinions about future events. These
forward-looking statements involve known and unknown risks and uncertainties
that may cause the actual results, performance or achievements of Compugen to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. </p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt;color:black'>&nbsp;</i></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt;color:black'>&nbsp;</i></p>
<p Style="color:black;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Some of these
risks are: changes in relationships with collaborators; the impact of
competitive products and technological changes; risks relating to the
development of new products; the ability to implement technological
improvements; the ability of Compugen to obtain and retain customers. These and
other factors are identified and more fully explained under the heading
&quot;Risk Factors&quot; in Compugen's annual reports filed on form 20F that
are filed with the Securities and Exchange Commission.</p>
<P Style="font-size:10.0pt;font-family:"Times New Roman"" align=center><B>1 </B>&nbsp;</P></div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image001.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 image001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``,"`@,"`@,#`P,$`P,$!0@%!00$
M!0H'!P8(#`H,#`L*"PL-#A(0#0X1#@L+$!80$1,4%145#`\7&!84&!(4%13_
MVP!#`0,$!`4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P``1"`"(`0$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]4Z***`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`$Z5%)*D".['8B_,S5CZKXOT?2'
M:"ZU?3;.\5<^3=7:1X_.O!=0U?XNW5]--:?%WX8V=J\F8;8Z:[^4O]W?]I^:
MMH4W(9T>K?MB_#G2-2NK.27Q#<O;L%:6S\.W\T3'_8=(2'_"J_\`PVM\-?\`
MGEXI_P#"6O\`_P",USO]I?&?_HM'PP_\%#?_`"36;KWC+XK>%]&NM5U3XW_"
MZUTZU7S)ISI#ML3_`(#<UZ,:%!]/_)O_`+4@[/\`X;5^&W_//Q3_`.$M?_\`
MQFJM]^VUX!M(5:UTKQGJLS,J+;VOA:\$C$^F]$7]:^:?%O[5>J>*=#FT[_AI
M;PUHJ3##WND>#K^&Y1/]AOGV5]&_LH_"?Q'X8TB3Q5XD^*>N_$=-6MTETP7C
M7$-O%;M\X?R97SO?(Y?I5UL+1PT.:K'\?_M1GONB7TFIZ3:WD]G<6$MQ$LC6
MUT%$L1_NMM/WJU***\484444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`5Q'Q*\9:]X)T>&XT'P=J'C6\DEV?8["XA@*)
M_>=Y6%=J>@KPC]H[2]+L8[;Q/K_Q2\6_#S1X$6R?^P)L6S.SMAW'DR?.?NY^
ME717-4Y1GENO:)%XJUF[U?6OV0)M4U6[;?<7EY>Z;--*W^^[U0_X0/1?^C+T
M_P#`C3?_`(NLO_A/?A7_`-'5_$/_`+_-_P#(='_">_"O_HZOXA_]_F_^0Z^B
M2GTA_P"G"31D\#Z'"CNW[&,,:+]YWNM+3_V>O)=?\$_$2;6KV70OV9/AG9:1
MYO\`HD5ZEG-.J?[;I<IO>NI\;^(?@WXA\(ZOI^H_M&>/?$UC-;OYFC/<_P#'
MWQO\GY[7^.OE_P`O]GO_`*`'Q5_\"+'_`.(KT\)%ROI_Z5_[=)&9]&?#OX9_
M$+7O'OA^P\1_`#X8:=H-Q>HE]=06=L[PP_Q[-ER_SU^C4$,<$*Q1*L<:+M55
M'W:_'?P+XP^!?PZ\:Z+XGT?0/BE_:FE7:7EOY\MCL=T_@?Y/N5^IOP9^-/AS
MXY^#8?$'AN=O+_U<]I.NR:UE_N2)V->3G%*K>$_L_P!?WI%0/0Z***^=+"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"F/&''S4^B@#R3Q_;_&`:\3X'/@=]%:/E?$$=VERC_]L?E=*YDP_M'_`/5*
M?^^;^O<[_3K?4;2:UNXTFMIT:*2-NC*W45\0W_@#X0V-_=6Z?LZ_%"X2&=HU
MFAM[LH_^TG^E?<KT,-*,U[R_#_@H1[7Y'[1_K\*?^^;^N(^(?PQ_:@\<S64M
MAX\\(^#9+9=KIH<EWLF_WT='KAO^$(^$7_1M?Q7_`/`>\_\`DR@>"?A#_P!&
MU_%?_P`![S_Y,KOBHP?-%_\`DL?_`)(#S#Q!XE^*WA76K[1]8_:N\-Z?J=E+
MY-S:W37"/$__`(#4S1_BK\1-(U:VO_\`AJ_P9J'D/O-K>?:&AE_V'46WW*O?
M%#P!I!O+-_`W[*'B#4T=7-Z_B9+Y'#?P;-ES7%?\(-XG_P"C.X?^^]4_^/5[
M</8SAK_[C(/TN^%'Q-T;XL>$H=:TC5M.UI4/V>YFTJ1GA2X51O5"RJW\7<5W
M0[FOF/\`87\/ZGHG@;Q`-2^&,?PK,NH_+ID;W#_:?W*?OOWSO_N?\`KZ=ZBO
MB\3"-*K*,#46BBBL1!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`444F:`&EACBL_5=9L="L)K[4;VWTZRB7=+<W4JQ1H/]MFZ5P?
MQ(\5_$W2[V*W\$^!=-\00D?O;W5-;6S0?[J*CO7G^L>(/CKXAM/LNJ?!KP1J
M-L6W>5>>)/.3_OA[:MH8=R]YM?>AFEX^_:)^'7B3P[-8>'/CGX6\*ZC*RXU-
M+RVN61?]A'?;7EG_``G5O_T>AI/_`(`Z574_V5\5O^C??AO_`.#I/_D6N$U3
MXQW6B:C/8:E\/O@C8WL#;)K6?Q;;H\+_`-QQ]FKUJ-)/W:?YQ)-'_A/(/^CS
M])_\`=*KCOB'^T)9?#NQAGD_:JO?$4\K!%L_#?A_3;V4_P"TW\*?BPKB?%WC
MGXD>(-5>?2/$GP)\+67\-G9WVG3$_P"^\J/N_"J&AQ_&_P`3ZK#IFB>./A'J
M^J2_ZJRLO[(FF?\`X`EM7K0PZ2YYRC_Y+_\`(D'FGC;Q_P##'XB^(KG7?$?Q
M;^)%YJMQLWRQZ/;PQC9]SY$N=B5TGP:^!_@SX]>(6T;P?X\^)=U(@WSZA/I4
M26MJOH[_`&C_`,<KZK^"_P"SG\7+O4H[WXG>(O#=G81'_D$Z+X>TYY;C_?F^
MS?(O^Y7U;HOA_3=`M7@TO3[33X7;>R6<*PHS>N%KGQ&:*C#DH/\`+_Y%%<IA
M_"[X>Z;\)_`ND>%]*>6>TTZ$1^?<ONEG;^*1SW9FR:[#[M.I#BOEIRYY<TBA
M:***0!1110`444E`"T444`%%%)0`M%%%`!1110`4444`%%%%`!1110`4444`
M-S7R+\:/B'\._B!XD%MKVF_%B-M)D>U5/#]AJ5M;.V[YG_<XW_[]?76*^8O$
ME[\1M.U_4K:3]H3P/HP2X<II]WHMOYUNAY1'W7.?NUU83XM?Z_!C/(_)^"__
M`$"_CI^>M?\`Q='D_!?_`*!?QT_/6O\`XNO3_P"W/B)_T<Q\/O\`P2VW_P`D
MT?VW\1/^CF/A]_X);;_Y)KV>9?S_`/DTO_D23P#XA:EX0TNSLSX*^'?QF\6S
M2NZ7$=]J^MV*0I_X_OKR'_A'-`_Z-5\8_P#@XU'_`.1J]H_:3N;R&71M2\7?
MM/QQ[R]M;Q^#-,?9_?\`WR6]S_X^]<+\(O"%I\8_'>G^&/#W[2?C:_U"XWS/
M#_9]]#^Y3YW^=[GY*]K#3C3H>T?_`+<9G1?`+]FSPU\:?$,EOJ'P#UCP5H5K
M_P`?6IZOXCOT?_<AA>%-[5]X_"'X#>!?@=I;67A#0+?3/-_UUT07N9C_`+<K
M?._XUUOA_0K7PMH-GI=L\QM;*%(4>YE:5]BC^)VY:OSG_:7_`."C/B2\\3:A
MX?\`AA/!I&BV;O`VNM"DLUVP^\\._P"14'_?=>#S8K-:OLZ7PE?`?I@/IBE.
M,<U^.WC?XJ_M)?":'PWK'BCQIK^F)KMO]MTY)KI'WI\GWX?X/OI\CU]F?LG_
M`+8W_"??!/Q3XC^($UO;W'A%E-_J%JFQ+B)TRC[.S]5V?[OK6-?**M"E[6,U
M)#YKGUXOL<TO3VK\FOB=^W]\6?BKXGCTWP1++X5L+J?[/8V&F0I->W.]]B;W
M?^/_`'*Y'6?VB?VB/@KXUFTOQ!XQUVSUJUV/+8:LR7*;'3>GR?.E=5/(<1.R
ME.*EV%SG[)\$\T<>M?(.F_M?7OC']B?Q/\28ECTGQ5IT4FF.(1N2.^^1$=-W
M4?OD>OC3PE^VK\>]5\5:19P>*;_7IY;R%4TR&PMM]W\_^I^2'^.N7#Y1B*_/
M;[`<Q^Q!Y/%'7I7XS_$7]KGXZW7C341J7BS5?"^H6MP\+Z+9?Z,EJZ?P;/\`
MXNNR\=?MJ_'36_A3X9N<3^&],F#VLWBFRMMCZM*IR?+?^#:O]SK\]=?]@8CW
M??CKYASGZS$XQCFC`QFOS<_8"_:=^(GB[XQGP?XG\07?B?2;RQFG1[_YY[=T
M^??O_N?P5YO\:?VWOBM8_%_QA;^&O&DFG^'[;4YK6QMTL[9T6%'V?QI_L&N=
M9+B/K$J'-JA\Y^MGY4$"OR#\??M/_M'S>`O#&L:KJ^J>']`O4>.RU>UMDMI-
M0?\`ONZ?7_83Y*^@_P#@GS^U3XO^(?B36?!OC757UQ+;3GU.TU.Y3]\J(Z(Z
M._\`']_K2K9/6HT?;<R:%S'WS^%(!CI7XZ>*?V[?C+<^(]7GTSQM<66EO=S/
M:6RV-L3%#O\`D3[G]ROH;]JC]H[XE?"+X4?!^PL/%4EKXQU73?[0UB]^RPM)
M*?+3Y-FS8OSN_P#WQ53R3$0G"#E\8^<_0;`XYI>_6OSN_8K_`&F_'_C#6_&_
MB+XC>,)[[P?X7T3[9<*]M#&@=W^0_)&G\"/7AWQ7_;N^*WQ-\33?\([K=YX4
MT9I=ECIVE_+.4_AWO]]G^G%$,EQ,ZLZ*^QN+F/V!I"<=Z_(CQ9^U5^TA\*;:
MR\)^)-;U#0M7A_TQ)K^TA>\EA;[B.[H^]/D?_;KZ&_8Q_:5\8Z[X-^(_CSXH
M^+)M1\,^'(H8XR]M"@#_`#O)LV(F]_N)_P`"%36R>K0H^VYHAS'WB"*#_G-?
ME)XK_;;^-'Q]\=P>'/A^\GAN"_N/)T_3=,1/M+]\S3/_`+//R;$KF=<_:&_:
M(_9Y^(D^C^)?%^H/J]EL>;3]3E2_MID=-Z?Y2MHY#B&N5SCS_P`O4.<_8(8I
M37Q%^TK^UWK=G^RWX#\:^$+QO#^N>*KB/&Q$F\E41S,GSI_?0)7S9\+OVR_V
MA==\4O!IFH7GC>Y2UE=-,33H63.S`F?8B/L3[]84<HQ%:E[9;(.8_6X>]!&<
MU^*:?ME_&NUU[^V/^%@ZJ\Z/YGV5PGV;/]SR=FS97[$_#[79_%_@3PYK=W"M
MM<ZEI]M>RPK_``NZ*^/UK#&Y;6P#C[3J$97.DVT4ZBO,+$%>!?&_X?6#:W;Z
MII?P)T+XFZA?[C?7MU)9V\L;)LV;S,GS_G_!7OU8OB;0T\3:!J&ERWEYIZW4
M30_:M.G\FXBS_%&^/E:M*=3V<N8#Y6_X0N[_`.C-_#G_`(,]*_\`B*/^$+NO
M^C-_#G_@STK_`.(KTC_AD^+_`**O\4O_``I3_P#$4?\`#)\7_15_BE_X4I_^
M(KTOK-/O_P"E?_)"/'O&7@+Q3?>'+VW\*_LI^%?#VN2(HM]0NKG2[B&([_XX
MMGS]ZUOV+M&\96?C+Q)<>+_#/@'17AM$A@?PG%8BYW;_`-XCFW=WV?*GWZ],
M_P"&48<?\E6^*7_A3'_XBK/P4_92\(?`?Q9KOB70;[6[[5=;C\N^FU:[6;S3
MOW[^$7YMU7/%TW0E#_Y+_P"2`Z#]I?4[S1?@!\0+[3MWVZ#1+DQF/[ZGRS7X
ML_#K2[+6/'_A?3]2N(K72[C4[:&XFF?8B0O,F_?_`,`K]Z+_`$^VU.RFM+J)
M+BVG1XI8I!N5T;AE-?$_C3_@E?X3UC6)[GP[XLU+PW9RMO\`L$MLMW''_L(^
M]'">V:Z\HS##X6,X5NI,HW*_[3'[9_PKT7X@CPY??#G3/B:FE0HBZB9;:2&%
MW^]"F]'_`-BN"_:*\7:9XN_8IL_$OA7X?V_P[TOQ!XDACN+6R1/]*AB2;9,^
MQ$^3>G_CE>J?#S_@EUX"\-:E#=>)=?U/Q7!"^]-/V):6S_[^SYW_`.^Z^I?&
M'PN\+^.O`UQX-UC1[>X\.S6ZVOV)$\M8T3[FS:/DV8&W'3%3+%8/#U*3H7ER
M[[_D4?D3^QE?^'M(_:0\*ZGXIU&UTK3+'SKK[1>3!(5F2%]GSG_;K%_:E^)E
MK\6OCQXM\3V$@ETR6X\BQF7HT,*;$?\`X'LW_P#`Z^R=<_X)1:!-?2/I'C[5
M+&R9LK#>6,5TZ?\``]Z5Z+\'_P#@G1\.?AEK-IK&KSWOC74K1O,B.IJB6R/_
M`'O)3A_^!EZ]R>;X*-7ZTI/GY;6,N29\E?$?0K_X0?L+>#_#FI1/9:IXRU]]
M;FM7^1TMT3Y-_P#Y!>L__@G?X9BUC]HB#6KI?]#\.Z9<ZE*\G\'R>2G_`*'7
MWC^TK^R)I?[3&LZ+>:OXCU/1H]*MY(8;:R2)T;>P+L=X_P!E/RK+^#_[#_A_
MX+Z#XWL-)\3ZO=77BC3O[->\FBA#VJ?O/N;$_P!OO_<KSHYK2^J3IOXYE\I^
M47COQ-+XT\9^(?$%Q\\VIWUS>O\`\#=WKZ:_;2`\"?";X%?#9/W<FGZ)_:=X
MG_3:78/_`$/SJ][T[_@E9X)L;^UN&\:Z].D,R2>0\5ML?9_!]RN_^/?["NA?
M'_X@/XIU7Q9K.ER"TBLXK*RCA\F)$STWH?[QKMGFV%G6H^][D/(CD/D__@GK
M`GA-/BS\2;A?W'ASP\Z0N_\`?;>__M'_`,?KY!DD>^F>6X?YY7WN_P#OU^C7
MQX^#VB_L?_L<^,=`T;5+K5)_%6J6]JUU>*BO\^P;/D_@V0O_`-]U\9_LR?"R
MU^,_QP\,>$]02633+MG>]$+['\E$=W^>O2P>(A4=?&/X/_D4,]L_;J^,GA#Q
M5X7^&O@;P+J]IK6E^'[+SKB:R??"C>2D,*?[^S?_`-]US_[)^GWO@WX8?&SX
MG>4Z6VF^'GT:TG_OW-QL^Y_N?)_WW7T+9_\`!*'PZFL^;<^/]6FTC?\`\>J6
M4*3[/[GG?_85]3?\*`\%0_!FZ^&5II8L_"EQ:O:M!"W[SY^LN[^_N^??ZUXE
M;,\+2P\,-0][77[[L.0_$[PC::?=^)]$M]5N$LM+>^A2[NG^Y##O3>__`'Q7
MMW[<7Q<T7XN?&][OPWJ":AH&E:?#IMK=0?<<IO=]G_`W_P#'*^GM'_X)3>'+
M;6$FU+QWJU_I*/N^Q16D<,S)_<,P/_LE;7B/_@ESX%US7+Z^LO$VLZ):SS;X
MM/M8H3#;I_<3<AKOGFV!G7A6<GH+DF?,/A;1+[PS_P`$_O&>N6ZL@\1^);2S
MF9.OV:$C'_D;->3_`+.FN>&_#/QR\&:QXKNTLM`T_4$N9YG5W1"B;T^1/]O9
M7Z"_&O5?!'['G[/GACX<ZWX7O_'WA;53<6<KM+'$[-O\[<_'WOG^79_<KXY\
M"W7[,6J^(+J7Q%IOCO0M/AB\Z*UDU!+M)G_YX_N8=_\`X_5X/$NM3KSY)<D^
MQ1B?M?\`QDL/CC\<=6U_1I7GT*&&'3[)W7;N1/X]O^V[O7H7B/0KSP9_P3K\
M-21*R+XH\4?;+M^[(J.D/_HB-Z^?/[*E^)GQ+?3_``EHOD/K&HNFF:3;?\L4
M=_D3_@"?QU^R9_9\\,:Q\"-+^%NO6W]H:/::=;V;NC;'\U%'[Y&_A??\^?>I
MS'$4<!##4UT)AU/R3_9Y^$T'Q@\97NE3^-K+P#]DL7N4U"\?9O\`G1-B?.G\
M#UN:C\,OA/\`VK-;S?'*XU"Z27R?.A\*WDWFO]SY'W_/7U5J/_!)O1;B];[#
M\1-1@L2V4ANM+BF=/^![T_\`0*]9^"'_``3[^'GP>URUUZYGOO%FNVI\RWN=
M2VI#;O\`WTA3^+W<O6=?.*"O4IU;OMRAR'QA^VUIJ?#K3OA/\+8+Q[R'PSH+
MW,T[P^3OFN'_`+G\'W*Z/]B+'@'X.?'+XDO^[EL=)_LVS?\`Z;,CO_Z&8:^I
M/CC^P)H'QU^)6I^,-4\7ZU8W5ZD,?V6WCA*0JB;/EWH:U]+_`&)_#^C?L^:O
M\)K7Q)J\&G:KJ!O[O4_+A^TO\Z'9C9MV_(G:N.>9X=X2%!2_Q?G(.0_)KP7X
M<E\8^+=!T*+YYM3OH;)/^!NB5^]VF:?#I=C:V=LOEP01)%&G]U5&!7R9\+O^
M"<7A+X7_`!#T'Q;#XIUG5)M'N/M,5M=10A&?^'[J#I7U^3@5Y^<8ZEC)P]CL
MBXQL/HINZBOGBQU%%%`!1110`4444`%%%%`!1110`4E+10`4444`%%%%`'GO
MQ5^"7A#XW:79Z;XSTLZM:6LWVF*'[1+%L?:5W?(X]:Y_X9_LH_#'X/\`B7_A
M(/"?AH:9J_E/;_:?M<TIV/\`>^^YKV#MZT'H*N->K&')S^Z,=1114""BBB@#
MD_'WPX\-_$_PW-H?BC1[36M*F;<UO=)GYL<,O]UN:\$G_P"";7P2FN/-72-4
MA7_GC'JLP3\LU]2CZT''I6]/%5Z*M2G89Y?\)_V;_AW\%M\OA+PO::7>NGER
M7S[IKIU]#,Y+_K7J!Z49%+UK&<YU)<TV(6BBBD`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
6444`%%%%`!1110`4444`%%%%`'__V3\_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
